Dose finding and safety analysis of inecalcitol in combination with docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients (pts)

被引：0
|
作者：
Medioni, J. [1 ]
Deplanque, G. [2 ]
Maurina, T. [3 ]
Ferrero, J. M. [4 ]
Rodier, J. M. [5 ]
Raymond, E. [5 ]
Allyon, J. [1 ]
Kalla, S. [2 ]
Dufour-Lamartinie, J. F. [6 ]
Oudard, S. [1 ]
机构：
[1] Hop Europeen Georges Pompidou, Paris, France
[2] Ctr Hosp St Joseph, Paris, France
[3] Ctr Hosp Univ Jean Minjoz, Besancon, France
[4] Ctr Antoine Lacassagne, F-06054 Nice, France
[5] Hop Beaujon, Clichy, France
[6] Hybrigenics, Oncol, Paris, France
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71408-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：415 / 415
页数：1
相关论文
共 50 条
  • [1] Dose finding and safety analysis of inecalcitol in combination with a docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients
    Medioni, J.
    Deplanque, G.
    Maurina, T.
    Ferrero, J. M.
    Rodier, J. M.
    Raymond, E.
    Allyon, J.
    Kalla, S.
    Dufour-Lamartinie, J. F.
    Oudard, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] Dose finding of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for castrate-resistant prostate cancer (HRPC) patients (pts)
    Medioni, J.
    Deplanque, G.
    Ferrero, J. M.
    Maurina, T.
    Rodier, J. M.
    Raymond, E.
    Allyon, G.
    Renaux, S.
    Dufour-Lamartinie, J. F.
    Oudard, S.
    EJC SUPPLEMENTS, 2010, 8 (07): : 136 - 136
  • [3] DOSE FINDING AND EFFICACY PHASE 2 STUDY OF INECALCITOL, A NEW VDR AGONIST, IN COMBINATION WITH DOCETAXEL-PREDNISONE REGIMEN FOR CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS (PTS)
    Medioni, Jacques
    Deplanque, Gael
    Maurina, Tristan
    Ferrero, Jean-Marc
    Rodier, Jean-Michel
    Raymond, Eric
    Ayllon, Jorge
    Renaux, Stephanie
    Dufour-Lamartinie, Jean-Francois
    Oudard, Stephane
    JOURNAL OF UROLOGY, 2011, 185 (04): : E285 - E286
  • [4] Sunitinib in combination with docetaxel and prednisone in patients (pts) with metastatic hormone-refractory prostate cancer (mHRPC)
    Zurita, A. J.
    Liu, G.
    Hutson, T.
    Kozloff, M.
    Shore, N.
    Wilding, G.
    Logothetis, C. J.
    Chen, I.
    Maneval, E. Chow
    George, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for patients (pts) with castration-resistant prostate cancer (CRPC).
    Medioni, J.
    Ferrero, J.
    Deplanque, G.
    Maurina, T.
    Rodier, J. P.
    Raymond, E.
    Allyon, J.
    Renaux, S.
    Dufour-Lamartinie, J.
    Oudard, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for castration-resistant prostate cancer (CRPC) patients (pts)
    Medioni, J.
    Deplanque, G.
    Ferrero, J.
    Maurina, T.
    Rodier, J. P.
    Raymond, E.
    Allyon, J.
    Renaux, S.
    Dufour-Lamartinie, J.
    Oudard, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [7] A retrospective analysis on 35 patients with hormone-refractory prostate cancer (HRPC) treated with docetaxel
    Carlini, P.
    Felici, A.
    Ruggeri, E. M.
    Moscetti, L.
    Chilelli, M.
    Ciccarese, M.
    Pino, M. S.
    Cecere, F. L.
    Nuzzo, C.
    Sperduti, I
    Pollera, C. F.
    Cognetti, F.
    ANNALS OF ONCOLOGY, 2006, 17 : XI82 - XI82
  • [8] SUNITINIB IN COMBINATION WITH DOCETAXEL AND PREDNISONE IN PATIENTS WITH METASTATIC HORMONE-REFRACTORY PROSTATE CANCER (MHRPC)
    Zurita, A. J.
    Logothetis, C. J.
    Liu, G.
    Wilding, G.
    Hutson, T. E.
    Chen, I.
    Chow-Maneval, E.
    George, D. J.
    ANNALS OF ONCOLOGY, 2008, 19 : 198 - 198
  • [9] PHASE 2A STUDY OF INECALCITOL, A VITAMIN D RECEPTOR AGONIST, FOR TREATMENT OF HORMONE-REFRACTORY PROSTATE CANCER (HRPC) PATIENTS (PTS)
    Medioni, J.
    Deplanque, G.
    Maurina, T.
    Ferrero, J. M.
    Rodier, J. M.
    Raymond, E.
    Allyon, J.
    Renaux, S.
    Dufour-Lamartinie, J. F.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2010, 21 : 43 - 43
  • [10] Weekly docetaxel for advanced hormone-refractory prostate cancer-HRPC
    Pepe, A.
    Usset, A.
    Calabria, C.
    Savio, G.
    Palmisano, V
    Leonardi, V
    Laudani, A.
    Arcuri, C.
    Giresi, A.
    Agostara, B.
    ANNALS OF ONCOLOGY, 2006, 17 : XI82 - XI82
12345